Sanofi: Renal Insufficiency, Chronic trials
The registry lists 20 Renal Insufficiency, Chronic studies with Sanofi as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 2Phase 2 5Phase 3 9Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney DiseaseCompletedNCT01574326Phase 2Results posted
- Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsCompletedNCT00985426Phase 3Results posted
- Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on HemodialysisCompletedNCT00853242Phase 2Results posted
- Severe Renal Disease Study in Fabry Patients Treated With FabrazymeTerminatedNCT00837824Phase 2Results posted
- An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD PatientsCompletedNCT02332811Phase 3
- Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With HyperphosphataemiaCompletedNCT01857024
- Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on HemodialysisCompletedNCT01736150Phase 3
- Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I TreatmentCompletedNCT01485900Phase 1
- Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney DiseaseCompletedNCT01282762
- Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on HemodialysisCompletedNCT01195246Phase 3
- A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on DialysisTerminatedNCT00833768Phase 3
- An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On DialysisCompletedNCT00681941Phase 3
- Cross-Over Study of Sevelamer Hydrochloride and Sevelamer CarbonateCompletedNCT00440648Phase 2
- Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure PatientsCompletedNCT00426712Phase 1
- Dialysis Clinical Outcomes Revisited (DCOR) TrialCompletedNCT00324571Phase 4
- Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer DosingCompletedNCT00324376Phase 2
- Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on HemodialysisCompletedNCT00268957Phase 3
- Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis PatientsCompletedNCT00267514Phase 3
- Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal DialysisCompletedNCT00196755Phase 3
- Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary HyperparathyroidismCompletedNCT00123461Phase 4